MedTrace Logo

Safety and Immunogenicity of Sars-cov-2 Vaccine in Patients With Rheumatic Diseases

NCT05191368 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-01-28

No results posted yet for this study

Summary

The purpose of this study was to preliminarily evaluate the immunogenicity of sars-cov-2 vaccine in patients with rheumatic diseases. The clinical information collection and blood sample testing of 100 healthy people and 200 patients with rheumatic diseases will be completed in Yunnan Traditional Chinese medicine hospital.

Research methods and procedures: clinical information collection and blood sample detection were carried out in healthy people and patients with rheumatic diseases, including systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic sclerosis (SSC), idiopathic inflammatory myopathy (IIM), systemic vasculitis and spinal arthritis

Conditions

  • Rheumatic Disease

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Yunnan University of Chinese Medicine

    lead OTHER

Principal Investigators

  • Fanying Meng · Yunnan University of Chinese Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-12
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191368 on ClinicalTrials.gov